Objective: Cisplatin is widely used for the treatment of non-small-cell lung cancer. However, it can cause unpleasant side effects and also requires prolonged hydration. We conducted a Phase II study of weekly gemcitabine and split-dose cisplatin in patients with advanced nonsmall-cell lung cancer (NSCLC) in order to reduce toxicity and shorten the time taken by administration. Our aims were to determine the response rate, toxicity and survival time with this regimen in patients with Stage IIIB/IV disease. Methods: Previously untreated patients with Stage IIIB/IV NSCLC were given gemcitabine (1000 mg/m 2 ) and split-dose cisplatin (40 mg/m 2 ) on days 1 and 8 at 3-week intervals for four cycles. Gemcitabine was administered over the course of 30 min, and cisplatin was over the course of 60 min on the same days on an outpatient basis. Results: Forty-five patients were enrolled, and all of them were assessable for response and toxicity. None had a complete response and 17 had a partial response (37.8%), for an overall response rate of 37.8% (95% confidence interval, 25.1 -52.4%). The survival rate was 56.5% at 1 year and 38.9% at 2 years, with a median survival time of 15.7 months. Leukopenia, neutropenia, anemia and thrombocytopenia were the most common toxic reactions, with Grade 3 reactions occurring at rates of 35%, 51%, 31% and 13%, respectively. Conclusions: Weekly gemcitabine and split-dose cisplatin is active and well tolerated in patients with Stage IIIB/IV NSCLC, administered on an outpatient basis without requiring prolonged hydration or hospitalization.
INTRODUCTION
Management of non-small-cell lung cancer (NSCLC) has improved considerably in the past decade. Several prospective trials and meta-analyses demonstrated that chemotherapy has statistically significant benefits in terms of survival as well as cancer-related symptoms, when compared with best supportive care (1, 2) . Recently, several randomized studies have shown that platinum-based doublets combined with third-generation agents further improve the outcomes of chemotherapy (3, 4) . On the basis of these data, recent American (5), Canadian (6) and European (7) guidelines for the treatment of advanced NSCLC recommend platinumbased third-generation chemotherapy for the first-line treatment.
Cisplatin is a widely used platinum derivative, but can cause serious and unpleasant side effects, such as nausea and vomiting, myelosuppression, neurotoxicity and renal impairment. Moreover, treatment with cisplatin requires prolonged hydration and hospitalization (8) . To overcome these limitations, many clinicians now use carboplatin, a less toxic platinum analogue with lower incidences of neurotoxicity, nephrotoxicity, and nausea and vomiting than cisplatin and no need for prolonged hydration (9) . Recently, however, Hotta et al. showed by a meta-analysis that cisplatin-based chemotherapy has a better response rate and survival than carboplatin-based chemotherapy (10) . They recommended that cisplatin-based third-generation regimens should remain the standard treatment.
Several randomized studies have reported that various platinum-based third-generation doublets have similar efficacy, with subtle differences in toxicity (11 -13) . Among platinum-based third-generation doublets, a meta-analysis by Le Chevaliera et al. (14) showed that a combination of gemcitabine and platinum resulted in better survival than other platinum-based regimens. However, cisplatin-based doublet regimen often induce 30 -40% Grade 3 -4 nausea/vomiting (12, 15) . We performed a Phase II trial to evaluate safety, toxicity, response and survival in patients with Stage IIIB/IV NSCLC who received weekly gemcitabine and split-dose cisplatin on an outpatient basis. The primary endpoint is response rate, and the secondary endpoints are toxicity and survival time.
PATIENTS AND METHODS

ELIGIBILITY
Patients with pathologically confirmed, Stage IIIB (with malignant pleural or pericardial effusion) or Stage IV NSCLC were eligible for the study. Other eligibility criteria included the following: (i) no previous treatment, including radiotherapy, chemotherapy, and surgery; (ii) lesions that could be measured or assessed; (iii) an age of 20 -70 years; (iv) an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2; and (v) a life expectancy of 3 months or longer. Patients also had to have an absolute granulocyte count of 2000/ml, a hemoglobin concentration of 9.5 g/dl, a platelet count of 100 000 and a serum creatinine level not exceeding the upper limit of normal or a 24 h creatinine clearance of at least 60 ml/min. In addition, the results of liver function tests had to be 2.5 times the upper limit of normal, the arterial oxygen partial pressure 60 torr and the cardiac function normal. Patients were excluded if they had apparent evidence of pulmonary fibrosis on computed tomography (CT) or if they were pregnant women. This study was approved by our institutional review board. All patients provided their written informed consent before enrollment. Before study entry, all patients underwent staging investigations, including physical examination, chest radiography, CT of the chest and abdomen, magnetic resonance imaging of the brain, [ 18 F]fluorodeoxyglucose positron emission tomography scanning and fiberoptic bronchoscopy with biopsy.
DRUG ADMINISTRATION
Patients received four cycles of chemotherapy with gemcitabine and cisplatin at 3-week intervals. Gemcitabine, at a dose of 1000 mg/m 2 , was administered over the course of 30 min on days 1 and 8. Cisplatin was administered at a split dose of 40 mg/m 2 , over the course of 60 min on the same days as gemcitabine. One thousand five hundred milliliters of normal saline solution were given intravenously over the course of 120 min before cisplatin administration. All patients were allowed to receive antiemetics with corticosteroids and 5-HT3 receptor antagonists. Chemotherapy was initiated within 5 days of the enrollment.
RESPONSE AND TOXICITY
During treatment, complete blood counts and serum chemical examinations were done once a week; urinalysis and chest radiography were performed at least weekly; and chest CT was done monthly. Toxicity was graded according to the ECOG common toxicity criteria. After treatment, the patients underwent physical examinations, comprising mainly chest radiography or CT, at 1-to 3-month intervals. Response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines.
DOSE ADJUSTMENTS AND EVALUATIONS DURING TREATMENT
Before each treatment with the study drugs, the dose was adjusted. Only one dose reduction was allowed during four cycles of chemotherapy. If the neutrophil count was ,1000/ml, the platelet count was ,75 000/ml or Grade 2 non-hematologic toxicity other than nausea/vomiting or alopecia occurred, subsequent treatment was delayed until the neutrophil count was .1000/ml, the platelet count was .75 000/ml or non-hematologic toxicity other than nausea/ vomiting or alopecia resolved to Grade 1. If the neutrophil count, the platelet count or non-hematologic toxicity other than nausea/vomiting did not recover within 21 days after drug administration, the patients were removed from the study. If febrile neutropenia, Grade 4 hematologic toxicity, or Grade 3 or 4 non-hematologic toxicity other than nausea/ vomiting or alopecia occurred during the cycle, the dose of gemcitabine was reduced to 800 mg/m 2 for the following cycle. If those kinds of toxicities were observed in patients treated with the reduced dose of gemcitabine, the patients were removed from the study. If serum creatinine level increased by .1.5 times the upper limit of normal during the cycle, the dose of cisplatin was reduced to 30 mg/m 2 . If serum creatinine increased up to the same level in patients treated with the reduced dose of cisplatin, the patients were removed from the study.
STATISTICAL ANALYSIS
This trial used a two-stage optimal design, as proposed by Simon, with an 80% power to accept the hypothesis and 5% significance to reject the hypothesis. Moreover, the trial was designed to detect a response rate of 40% when compared with a minimal, clinically meaningful response rate of 20%. Allowing for follow-up losses of two patients, the total Sixteen patients received second-line treatment. Ten of them received gefitinib and the rest received docetaxel alone.
TOXICITY
Toxicity is summarized in Table 3 . Leukopenia was the most clinically significant toxicity and occurred in conjunction with neutropenia. Grade 3 or 4 leukopenia or neutropenia occurred in 16 (35%) and 23 (51%) patients, respectively. Febrile neutropenia occurred in two patients, and these two patients were admitted to the hospital. Grade 4 thrombocytopenia was not seen in any patients. As for non-hematologic Large cell carcinoma 1 (2)
Not specified 3 (7) 
Values in parentheses are expressed in percentages. 2 ) on day 1 of a 4-week cycle. The incidences of Grade 3 or 4 nausea or vomiting were 27% and 23%, respectively (16) . In the ECOG trial reported by Schiller et al. (12) , using the same regimen as Sandler et al. (16) , the incidences of Grade 3 or 4 nausea or vomiting were 37% and 35%, respectively. As for hematologic toxicity, the incidence of Grade 3 or 4 neutropenia or thrombocytopenia was 50-60%.
In the aim of reducing the occurrence of severe nausea/ vomiting, we performed a Phase II trial of the split-dose cisplatin with gemcitabine. In fact, there have been no reports on dose-escalation study of split-dose cisplatin in our knowledge, and we did not have the result of the Phase I trial before the present trial. However, split-dose administration of weekly cisplatin has been considered as a potential method of treatment to sustain efficacy and reduce toxicity (17 -21 2 ) plus gemcitabine (1000 mg/m 2 ). The incidence of Grade 3 or 4 emesis was 2.1% (19) . In our study, the incidence of Grade 3 nausea/ vomiting was 7% and Grade 4 was not observed. The incidence and the severity of Grade 3 or 4 nausea/vomiting were lower than those reported previously for conventional regimens of cisplatin plus gemcitabine. The milder nausea/ vomiting is attributed to split-dose cisplatin.
Response rate and survival time with this regimen were promising: the 1-and 2-year survival rates were 56.5% and 38.9%, respectively, with a median survival time of 15.7 months. It has been suggested from our trial as with other clinical trails (18, 19) incorporating split-dose cisplatin that for patients with advanced NSCLC Stage IIIB/IV disease, split-dose cisplatin with gemcitabine could be active, and more acceptable, with lower rates of severe nausea/vomiting. Weekly gemcitabine and split-dose cisplatin can also offer outpatient treatment to the patient, thereby contributing to the improvement of quality of life. Randomized Phase III trial is awaited to further support the efficacy and safety of split-dose cisplatin with gemcitabine. 
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